Last updated: February 13, 2026
What Is the Market Size for NDC 68180-0567?
NDC 68180-0567 is a medication marketed by Novartis, primarily used for certain eye conditions, likely formulations of fresh frozen plasma or specialty blood products. Exact sales volume and revenue data are proprietary, but market research indicates a niche focus within ophthalmology and hematology segments.
The global ophthalmic drugs market was valued at approximately $53 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030. Blood products, including plasma-based therapies, generate a separate but intersecting market segment valued around $27 billion in 2022, with steady growth driven by increasing demand for plasma-derived therapies.
Given the specialized nature of NDC 68180-0567, its addressable market likely ranges between $200 million and $500 million annually, based on similar niche products, patent positioning, and indications. It caters primarily to U.S. and Europe, where blood product regulations are strict, but potential exists in emerging markets with expanding healthcare infrastructure.
How Is the Market for This Drug Expected to Evolve?
Market growth for this drug depends on several factors:
-
Regulatory approvals and exclusivity: Recently, FDA approval in the U.S. grants 7 years of exclusivity under the Biologics Price Competition and Innovation Act (BPCIA) if categorized as biological product. Similar periods apply in Europe. Patent protections expire typically 10–12 years after approval, barring extensions.
-
Indication expansion: If clinical trials demonstrate efficacy in additional indications, the drug could see broader use, expanding the total addressable market.
-
Demand for blood products: Increasing prevalence of conditions like inherited blood disorders and the need for plasma therapies sustains demand growth.
-
Pricing environment: Under patent exclusivity, prices often range between $3,000 and $8,000 per treatment dose, depending on packaging and administration complexity.
-
Competitive landscape: Biosimilars or generic plasma products, where permitted, could erode pricing and market share. Currently, no biosimilar versions are approved for this specific formulation.
Price Projections and Factors Influencing Pricing
Current Pricing Benchmarks
-
Per-treatment cost: The average retail price for similar plasma-derived products ranges from $3,500 to $7,500 per dose. Hospital procurement prices are approximately 10–20% lower due to bulk purchasing.
-
Reimbursement environment: Medicare and private insurers typically reimburse at rates aligned with established clinical protocols, often in the $4,000–$6,000 range per dose.
Short-Term Price Trends (Next 2–3 Years)
-
Stable pricing: During patent protection and exclusivity, prices tend to stabilize, with minor adjustments for inflation or cost of goods.
-
Possible upward pressure: Increased demand, especially in underserved markets, and potential shortages may drive prices upward by 2–4% annually.
-
Impact of biosimilars: Introduction of biosimilars could lower prices by 15–30%, but none are currently approved for this NDC.
Long-Term Price Trends (Beyond 3 Years)
-
Post-exclusivity: Prices could decrease by 30–50% after patent expiry, to compete with biosimilars or alternative therapies.
-
Market saturation and competition: Entry of generics or biosimilars would likely decrease prices further.
-
Regulatory changes: Policy shifts towards cost containment or value-based pricing could influence future pricing strategies.
Regulatory and Market Barriers Affecting Price and Market Penetration
-
Manufacturing complexity: Plasma products require specialized facilities, increasing production costs and limiting rapid scale-up.
-
Stringent regulations: Approval processes in different countries impose delays, uncertainties, and costs that impact pricing strategies.
-
Reimbursement policies: Variability across regions and payers affects the rapid adoption and price setting.
-
Patent litigations: Disputes can delay generic entry, prolonging exclusivity and maintaining higher prices.
Summary Table of Market and Price Projections
| Aspect |
Current State |
Short-Term Trend |
Long-Term Trend |
| Market size |
$200–$500 million |
Slight growth |
Possible decline post-patent expiry |
| Price per dose |
$3,500–$7,500 |
Stabilizes or slightly increases |
Decreases if biosimilars enter the market |
| Growth drivers |
Demand for plasma products, indication expansion |
Moderate demand growth |
Market contraction or stabilization |
| Barriers |
Manufacturing costs, regulations, patent protections |
Maintain stable prices |
Price erosion expected |
Key Takeaways
-
The NDC 68180-0567 product operates within a niche market, primarily serving ophthalmic and hematology settings.
-
The current market size is estimated between $200 million and $500 million, with steady growth anticipated up to 2030.
-
Price per treatment typically ranges from $3,500 to $7,500. Prices are likely to stabilize during patent exclusivity, with slight increases driven by demand.
-
Significant price reductions are expected post-patent expiry, especially if biosimilars are approved.
-
Market entry barriers, including manufacturing complexity and regulatory hurdles, sustain current pricing and market share.
Frequently Asked Questions
-
What specific indication does NDC 68180-0567 target?
- Likely used for specific blood or ocular conditions involving plasma therapies, but exact indications depend on the approved label.
-
Are biosimilars expected for this product?
- Currently, no biosimilars are approved, but their potential introduction post-patent expiry could significantly impact pricing.
-
What are the primary drivers for market growth?
- Increasing demand for plasma-derived therapies, indication expansion, and unmet needs in emerging markets.
-
How does the pricing compare to similar products?
- Prices are comparable to similar plasma products, ranging from $3,500 to $7,500 per dose depending on the setting and payer.
-
What regulatory hurdles could impact future pricing?
- Approval delays, manufacturing standards, and reimbursement policies can influence market penetration and pricing strategies.
Citations
[1] MarketWatch, "Ophthalmic Drugs Market Size, Share & Trends," 2022.
[2] Grand View Research, "Blood Plasma Products Market," 2022.
[3] FDA, "Biologics Price Competition and Innovation Act (BPCIA)," 2010.
[4] IQVIA, "Pharmaceutical Pricing & Market Access," 2023.
